SoniVie, a Tel Aviv, Israel-based medical device company, raised $60M in Series C funding.
The round was led by Andera Partners, with participation from Supernova Invest, Omega Funds and TechWald.
The company intends to use the funds to support its clinical and regulatory path towards pre-market approval of its TIVUS technology for the treatment of hypertension.
Led by CEO Tomaso Zambelli, SoniVie is a medical device company developing TIVUS, an ultra-sound denervation platform with active development programs in three therapeutic areas: pulmonary artery denervation for pulmonary hypertension, renal artery denervation for resistant hypertension, and lung denervation for chronic obstructive pulmonary disease with chronic bronchitis.
Following this financing, the Board of Directors of the company is chaired by Zvika Slovin and composed of directors appointed by Andera Partners (Raphaël Wisniewski), Omega Funds (Claudio Nessi), Supernova Invest (Rémi Spagnol) and TechWald Holding (Alessandro Piga), Sonivie CEO Tomaso Zambelli and independent directors Raymond W. Cohen (CEO of Axonics) and Zeev Zehavi (former executive JJDC).
SoniVie has operations in Israel, US and Europe.
FinSMEs
09/01/2023